Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 56, Issue 3, 2011, Pages 361-367

  Egbelakin, Akinbode ^a   Ferguson, Michael J ^a   MacGill, Emily A ^a   Lehmann, Amalia S ^a   Topletz, Ariel R ^a   Quinney, Sara K ^a   Li, Lang ^a   McCammack, Kevin C ^a   Hall, Stephen D ^a   Renbarger, Jamie L ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Peripheral neuropathy; Pharmacogenetics; Vincristine

Indexed keywords

CYTOCHROME P450 3A5; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA EXTRACTION; DRUG METABOLISM; GENE EXPRESSION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHY; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DNA, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; INFANT; METABOLIC CLEARANCE RATE; NEUROTOXICITY SYNDROMES; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TISSUE DISTRIBUTION; VINCRISTINE;

EID: 78651110078     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22845     Document Type: Article

References (30)

1. McCune JS, Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am J Health Syst Pharm 1997; 54: 1755-1758.
2. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999; 44: 203-209.
3. Van den Berg HW, Desai ZR, Wilson R, et al. The pharmacokinetics of vincristine in man: Reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982; 8: 215-219.
4. Frost BM, Lonnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: No pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 2003; 92: 551-557.
5. Crom W, de Graaf S, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphoblastic leukemia. J Pediatr 1994; 125: 642-649.
6. Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007; 321: 553-563.
7. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metabolism Disposition. 2006; 34: 1317-1327.
8. Gidding CE, Kellie SJ, Kamps WA, et al. Vincristine revisited. Crit Rev Oncol Hematol 1999; 29: 267-287.
9. Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000; 28: 1121-1127.
10. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996; 31: 184-197.
11. Leveque D, Jehl F, Quoix E, et al. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 1992; 32: 1096-1098.
12. Marquet P, Lachatre G, Debord J, et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992; 42: 545-547.
13. Rahmani R, Bruno R, Iliadis A, et al. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). Cancer Res 1987; 47: 5796-5799.
14. Ratain MJ, Vogelzang NJ, Sinkule JA. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther 1987; 41: 61-67.
15. Sethi VS, Jackson DV, Jr., White DR, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 1981; 41: 3551-3555.
16. Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 1994; 21: 21-27.
17. Zhou XJ, Placidi M, Rahmani R. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 1994; 14: 1017-1022.
18. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
19. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-272.
20. Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008; 50: 769-771.
21. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004; 60: 231-236.
22. Dennison JB, Renbarger JL, Walterhouse DO, et al. Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit 2008; 30: 357-364.
23. Aytac S, Yetgin S, Tavil B. Acute and long-term neurologic complications in children with acute lymphoblastic leukemia. Turk J Pediatr 2006; 48: 1-7.
24. Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 1999; 39: 323-330.
25. Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994; 125: 642-649.
26. de Graaf SS, Bloemhof H, Vendrig DE, et al. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1995; 24: 235-240.
27. Lonnerholm G, Frost BM, Abrahamsson J, et al. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol 2008; 142: 616-621.
28. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003; 61: 1297-1300.
29. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006; 11: 135-141.
30. Smith E. Clinimetric evaluation of peripheral neuropathy measurement approaches. Salt Lake City: University of Utah; 2008.